Ocular Therapeutix names interim CFO, grants stock options

Ocular Therapeutix announced that its Chief Financial Officer and Chief Operating Officer, Donald Notman, has taken a temporary medical leave of absence effective January 20, 2026.

Rhea-AI Filing Summary

Ocular Therapeutix announced that its Chief Financial Officer and Chief Operating Officer, Donald Notman, has taken a temporary medical leave of absence effective January 20, 2026. To ensure continuity in its finance function, the Board appointed Jason Robins, previously Senior Vice President, Finance, as interim Chief Financial Officer, also serving as principal financial and principal accounting officer until Mr. Notman’s anticipated return.

In connection with this interim role, Mr. Robins received a stock option to purchase 33,000 shares of common stock at an exercise price of $11.45 per share, vesting in equal monthly installments over four years under the 2021 Stock Incentive Plan. The company notes there are no related-party transactions or family relationships involving Mr. Robins, and that he entered into its standard indemnification agreement covering certain legal expenses related to his service.

Insights

Corporate governance and leadership analyst

Temporary CFO change with internal successor and routine equity grant appears neutral.

The company discloses that its CFO/COO, Donald Notman, has taken a temporary medical leave as of January 20, 2026, and that Senior Vice President, Finance, Jason Robins is stepping in as interim CFO and principal accounting officer. Because the replacement is internal and described as interim with an anticipated return of Mr. Notman, this reads as a continuity-focused leadership adjustment rather than a strategic shift.

Mr. Robins receives a stock option for 33,000 shares at an exercise price of $11.45 per share, vesting over four years, which aligns with standard executive incentive practices. The filing also clarifies there are no related-party transactions or special arrangements tied to his appointment and that he is covered by the standard indemnification agreement. Overall, the information is governance-related and specific but does not, by itself, indicate a material change in the company’s financial outlook.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

What leadership change did Ocular Therapeutix (OCUL) disclose in this 8-K?

The company disclosed that Chief Financial Officer and Chief Operating Officer Donald Notman began a temporary medical leave of absence effective January 20, 2026, and that Jason Robins, Senior Vice President, Finance, was appointed interim Chief Financial Officer and will act as principal financial and principal accounting officer during this period.

Who is Jason Robins, the new interim CFO of Ocular Therapeutix (OCUL)?

Jason Robins, age 49, has served as Ocular Therapeutix’s Senior Vice President, Finance since January 2025, overseeing accounting, reporting, financial planning and analysis, and corporate planning. Previously, he was Vice President, Finance at Fusion Pharmaceuticals Inc. from October 2020 to December 2024.

What equity compensation did Jason Robins receive in connection with his interim CFO role at OCUL?

In connection with his appointment as interim Chief Financial Officer, Jason Robins was granted an option to purchase 33,000 shares of Ocular Therapeutix common stock at an exercise price of $11.45 per share, vesting in equal monthly installments over four years under the company’s 2021 Stock Incentive Plan, as amended.

Are there any related-party transactions or special arrangements linked to Jason Robins’ appointment at Ocular Therapeutix (OCUL)?

The company states there is no arrangement or understanding with any other person pursuant to which Jason Robins was appointed, and that there are no related-party transactions reportable under Item 404(a) of Regulation S-K and no family relationships between him and any directors or officers.

What indemnification protections does Jason Robins have as interim CFO of OCUL?

Jason Robins entered into Ocular Therapeutix’s standard form of Indemnification Agreement, under which the company may be required to indemnify him for certain expenses, attorneys’ fees, judgments, fines, and settlement amounts arising from actions or proceedings related to his service to the company.

Does this Ocular Therapeutix (OCUL) 8-K indicate that the CFO change is permanent?

No. The filing describes Donald Notman’s status as a temporary medical leave of absence and states that Jason Robins will serve as interim Chief Financial Officer until Mr. Notman’s anticipated return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 07:00 AM Learn about SEC filing dates

false 0001393434 0001393434 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2026

OCULAR THERAPEUTIX, INC.

(Exact Name of Company as Specified in Charter)

Delaware		001-36554		20-5560161
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15 Crosby Drive

Bedford, MA 01730

(Address of Principal Executive Offices) (Zip Code)

Company’s telephone number, including area code: (781) 357-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		OCUL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of January 20, 2026, Donald Notman, Chief Financial Officer and Chief Operating Officer (principal financial officer and principal accounting officer) of Ocular Therapeutix, Inc. (the “Company”), is taking a temporary medical leave of absence from the Company.

Accordingly, effective as of January 20, 2026 (the “Robins Effective Date”), the Company’s Board of Directors appointed Jason Robins, the Company’s Senior Vice President, Finance, to serve as the Company’s interim Chief Financial Officer until Mr. Notman’s anticipated return. Mr. Robins will serve as the Company’s principal financial officer and principal accounting officer during this period. In connection with his appointment as interim Chief Financial Officer, on the Robins Effective Date, Mr. Robins was granted an option to purchase an aggregate of 33,000 shares of the Company’s common stock at an exercise price of $11.45 per share, the closing sale price (for the primary trading session) of the Company’s common stock on the Nasdaq Global Market on the Robins Effective Date. The stock option vests and becomes exercisable over four years in equal monthly installments until the fourth anniversary of the grant date, subject to the terms and conditions of the Company’s 2021 Stock Incentive Plan, as amended.

Mr. Robins, age 49, has served as the Company’s Senior Vice President, Finance, since January 2025, where he has managed accounting, reporting, financial planning and analysis, and corporate planning. From October 2020 to December 2024, Mr. Robins served as Vice President, Finance, of Fusion Pharmaceuticals Inc., a biopharmaceutical company acquired by AstraZeneca in June 2024. Mr. Robins received a Bachelor of Science from Babson College, a Master of Science from the Harvard-MIT Division of Health Sciences and Technology, and a Master of Business Administration from the MIT Sloan School of Management.

There is no arrangement or understanding between Mr. Robins and any other person pursuant to which Mr. Robins was appointed as an officer. There are no related party transactions between the Company and Mr. Robins reportable under Item 404(a) of Regulation S-K and no family relationships between Mr. Robins and any of the Company’s directors or officers.

In connection with his interim appointment, Mr. Robins has entered into the Company’s standard form of Indemnification Agreement, a copy of which was filed as Exhibit 10.12 to the Company’s Registration Statement on Form S-1 (File No. 333-196932) filed with the Securities and Exchange Commission on June 20, 2014. Pursuant to the terms of such indemnification agreement, the Company may be required, among other things, to indemnify Mr. Robins for expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service to the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OCULAR THERAPEUTIX, INC.
Date: January 23, 2026	By:	/s/ Todd Anderman
		Todd Anderman
		Chief Legal Officer